Neurocrine Biosciences, Inc.
NBIX
Rang in Aktien
#1509
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
Aktienkurs
$141.77
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$14.41B
Veränderung (1 Tag)
3.49%
Veränderung (1 Jahr)
-0.62%
Land
US
Handel Neurocrine Biosciences, Inc. (NBIX)
Kategorie
Healthcare
Umsatz von Neurocrine Biosciences, Inc. (NBIX)
Umsatz im Jun 2026 TTM: $3.37B
Laut den aktuellen Finanzberichten von Neurocrine Biosciences, Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $3.37B. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $2.36B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $1.89B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Neurocrine Biosciences, Inc. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $3.37B | 17.95% |
| 2025 | $2.86B | 21.45% |
| 2024 | $2.36B | 24.81% |
| 2023 | $1.89B | 26.76% |
| 2022 | $1.49B | 31.34% |
| 2021 | $1.13B | 8.38% |
| 2020 | $1.05B | 32.71% |
| 2019 | $788.10M | 74.67% |
| 2018 | $451.20M | 179.16% |
| 2017 | $161.63M | 977.51% |
| 2016 | $15.00M | -24.12% |
| 2015 | $19.77M | 0.00% |
| 2014 | 0.00 | -100.00% |
| 2013 | $2.92M | -94.51% |
| 2012 | $53.14M | -31.36% |
| 2011 | $77.41M | 131.08% |
| 2010 | $33.50M | 1,034.47% |
| 2009 | $2.95M | -25.71% |
| 2008 | $3.98M | 224.75% |
| 2007 | $1.22M | -96.88% |
| 2006 | $39.23M | -68.33% |
| 2005 | $123.89M | 45.45% |
| 2004 | $85.18M | -38.76% |
| 2003 | $139.08M | 670.73% |
| 2002 | $18.05M | -56.25% |
| 2001 | $41.24M | 182.71% |
| 2000 | $14.59M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $12.62B | 274.18% |
US
|
|
| $2.23B | -33.96% |
US
|
|
| $15.74B | 366.65% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 78.47% |
NL
|
